<DOC>
	<DOC>NCT00083694</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.</brief_summary>
	<brief_title>Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia</brief_title>
	<detailed_description>Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS. Signed informed consent, including patient agreeing to use safe contraceptive methods during the treatment and for at least 4 months after the treatment is completed Serum creatinine &lt; or = 2.5mg/dL Serum bilirubin&lt; or = 2.5mg/dL Negative pregnancy test Age 18 years or older Performance status &lt; or = 3 Pregnant or lactating women Concurrent treatment with cytotoxic chemotherapy, or radiation History of seizures, neurotoxicity, or active CNS disease Serious infections not controlled by antibiotics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>relapsed</keyword>
</DOC>